Skip to main content

Table 2 Uni- and multivariate analysis (Cox regression, Enter method)

From: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

  n Univariate P-value Multivariate
Enter
P-value
HR (death) (95% CI) HR (death) (95% CI)
Agea
 < 70 82 0.99 (0.56–1.76) 0.98 0.76 (0.38–1.5) 0.43
 ≥ 70 27
ECOGa
 0 77 0.46 (0.27–0.77) 0.002 0.68 (0.39–1.19) 0.18
 > 0 33
BRAFa
 Mutated 56 0.56 (0.34–0.93) 0.02 0.58 (0.32–1.05) 0.07
 Wild type/unknown 53
Number of brain metastasesa
 1 47 1.25 (0.85–1.82) 0.29 1.5 (0.425–4.98) 0.30
 2–4 52
 > 4 10
Extracranial metastasesa
 present 82 0.42 (0.56–1.76) 0.02 1.35 (0.37–4.98) 0.65
 absent 27
Brain metastases volume
 < 1.5 cc 54 0.56 (0.34–0.94) 0.03 0.54 (0.29–0.96) 0.04
 ≥ 1.5 cc 55
Timing
 Synchronous 25 1.84 (1.05–3.24) 0.03 2.43 (1.24–4.75) 0.01
 metachronous 84
Systemic therapy
 IT 67 1.99 (0.37–8.48) 0.001 3.0 (0.98–9.26) 0.005
 IT 34
 combination 8
Other metastases controlled
No 38 0.25 (0.01–1.97) 0.001 0.15 (0.01–12.18) 0.78
yes 34
mixed 17
no other metastases 19
  1. Abbreviations: HR Hazard ratio, CI Confidence interval; a = factors in the original molGPA score